COST-MINIMIZATION OF VILANTEROL / UMECLIDINIUM VERSUS OLODATEROL / TIOTROPIUM IN THE BASIC THERAPY OF SEVERE AND VERY SEVERE COPD
The recently introduced novel drug combinations for the treatment of COPD are based on long-acting beta-agonists (vilantererol / umeclidinum bromide) and long-acting anticholinergics (olodaterol / tiotropium bromide). In addition to their beneficial clinical effects, these medications have an impact...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IRBIS LLC
2017-08-01
|
| Series: | Фармакоэкономика |
| Subjects: | |
| Online Access: | https://www.pharmacoeconomics.ru/jour/article/view/196 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849696841782788096 |
|---|---|
| author | E. G. Kosolapov F. S. Kochenkov N. L. Pogudina D. V. Blinov N. L. Bondarenko A. V. Karaulov |
| author_facet | E. G. Kosolapov F. S. Kochenkov N. L. Pogudina D. V. Blinov N. L. Bondarenko A. V. Karaulov |
| author_sort | E. G. Kosolapov |
| collection | DOAJ |
| description | The recently introduced novel drug combinations for the treatment of COPD are based on long-acting beta-agonists (vilantererol / umeclidinum bromide) and long-acting anticholinergics (olodaterol / tiotropium bromide). In addition to their beneficial clinical effects, these medications have an impact on COPD treatment costs. Minimizing the costs of highly effective medications is necessary to improve the public medical care and drug supply.Objective: to identify the key differences between vilantererol / umeclidinum bromide and olodaterol / tiotropium bromide, and evaluate the ways of minimizing health budget expenditures.Materials and methods. We used the available information from research, clinical trials, and instructions for medical use to conduct a cost analysis that was based on the prices for these medications at different levels of drug supply. As a result, the impact on the healthcare budget was determined under conditions of choosing the least expansive medication and adding vilantererol / umeclidinum bromide in the list of VED.Results. According to the network meta-analysis, when compared with mono-component drugs, vilantererol / umeclidinum bromide showed a more favorable effect on cardiovascular events, as well as a more pronounced effect on the volume of forced exhalation in the first second (FEV1). For the olodaterol / tiotropium bromide combination, no such trend was seen. The costs of 12-month therapy with vilantererol / umeclidinum bromide and with olodaterol / tiotropium bromide were 27,541 and 36,120 rubles, respectively (a difference of 24%). The average direct medical costs were 32,753 and 41,333 rubles per patient per year, respectively. If the vilantererol / umeclidinum bromide combination is added to the VED list and the manufacturer’s maximum selling price is registered at the level of the reference countries, the savings can reach 3-5%.Conclusion. In patients with severe and extremely severe COPD, and also when COPD monotherapy in patients without severe symptoms (FEV1 ≥50%, CAT <10 scores, mMRC <2) or with mild to moderate symptoms (FEV1 ≥50%) is not effective, the use of vilantererol / umeclidinum bromide in place of olodaterol / tiotropium bromide is more promising in terms of minimizing health budget spending. |
| format | Article |
| id | doaj-art-1d4f89ad2f9c43b4acf1d67df41135bb |
| institution | DOAJ |
| issn | 2070-4909 2070-4933 |
| language | Russian |
| publishDate | 2017-08-01 |
| publisher | IRBIS LLC |
| record_format | Article |
| series | Фармакоэкономика |
| spelling | doaj-art-1d4f89ad2f9c43b4acf1d67df41135bb2025-08-20T03:19:20ZrusIRBIS LLCФармакоэкономика2070-49092070-49332017-08-01102223010.17749/2070-4909.2017.10.2.022-030173COST-MINIMIZATION OF VILANTEROL / UMECLIDINIUM VERSUS OLODATEROL / TIOTROPIUM IN THE BASIC THERAPY OF SEVERE AND VERY SEVERE COPDE. G. Kosolapov0F. S. Kochenkov1N. L. Pogudina2D. V. Blinov3N. L. Bondarenko4A. V. Karaulov5Independent Research Company «Smart Choice»Independent Research Company «Smart Choice»Independent Research Company «Smart Choice»N.I. Pirogov Russian National Research Medical UniversityI.M. Sechenov First Moscow State Medical University, Health Ministry of Russian Federation; Clinical Hospital № 85, FMBA of RussiaI.M. Sechenov First Moscow State Medical University, Health Ministry of Russian FederationThe recently introduced novel drug combinations for the treatment of COPD are based on long-acting beta-agonists (vilantererol / umeclidinum bromide) and long-acting anticholinergics (olodaterol / tiotropium bromide). In addition to their beneficial clinical effects, these medications have an impact on COPD treatment costs. Minimizing the costs of highly effective medications is necessary to improve the public medical care and drug supply.Objective: to identify the key differences between vilantererol / umeclidinum bromide and olodaterol / tiotropium bromide, and evaluate the ways of minimizing health budget expenditures.Materials and methods. We used the available information from research, clinical trials, and instructions for medical use to conduct a cost analysis that was based on the prices for these medications at different levels of drug supply. As a result, the impact on the healthcare budget was determined under conditions of choosing the least expansive medication and adding vilantererol / umeclidinum bromide in the list of VED.Results. According to the network meta-analysis, when compared with mono-component drugs, vilantererol / umeclidinum bromide showed a more favorable effect on cardiovascular events, as well as a more pronounced effect on the volume of forced exhalation in the first second (FEV1). For the olodaterol / tiotropium bromide combination, no such trend was seen. The costs of 12-month therapy with vilantererol / umeclidinum bromide and with olodaterol / tiotropium bromide were 27,541 and 36,120 rubles, respectively (a difference of 24%). The average direct medical costs were 32,753 and 41,333 rubles per patient per year, respectively. If the vilantererol / umeclidinum bromide combination is added to the VED list and the manufacturer’s maximum selling price is registered at the level of the reference countries, the savings can reach 3-5%.Conclusion. In patients with severe and extremely severe COPD, and also when COPD monotherapy in patients without severe symptoms (FEV1 ≥50%, CAT <10 scores, mMRC <2) or with mild to moderate symptoms (FEV1 ≥50%) is not effective, the use of vilantererol / umeclidinum bromide in place of olodaterol / tiotropium bromide is more promising in terms of minimizing health budget spending.https://www.pharmacoeconomics.ru/jour/article/view/196chronic obstructive pulmonary diseasecopdlong-acting beta-agonistslabalong-acting anticholinergicslaacvilantererolumeclidinum bromideolodateroltiotropium bromidefixed combinationcost minimization analysiscost-effectiveness analysisbudget impact analysis |
| spellingShingle | E. G. Kosolapov F. S. Kochenkov N. L. Pogudina D. V. Blinov N. L. Bondarenko A. V. Karaulov COST-MINIMIZATION OF VILANTEROL / UMECLIDINIUM VERSUS OLODATEROL / TIOTROPIUM IN THE BASIC THERAPY OF SEVERE AND VERY SEVERE COPD Фармакоэкономика chronic obstructive pulmonary disease copd long-acting beta-agonists laba long-acting anticholinergics laac vilantererol umeclidinum bromide olodaterol tiotropium bromide fixed combination cost minimization analysis cost-effectiveness analysis budget impact analysis |
| title | COST-MINIMIZATION OF VILANTEROL / UMECLIDINIUM VERSUS OLODATEROL / TIOTROPIUM IN THE BASIC THERAPY OF SEVERE AND VERY SEVERE COPD |
| title_full | COST-MINIMIZATION OF VILANTEROL / UMECLIDINIUM VERSUS OLODATEROL / TIOTROPIUM IN THE BASIC THERAPY OF SEVERE AND VERY SEVERE COPD |
| title_fullStr | COST-MINIMIZATION OF VILANTEROL / UMECLIDINIUM VERSUS OLODATEROL / TIOTROPIUM IN THE BASIC THERAPY OF SEVERE AND VERY SEVERE COPD |
| title_full_unstemmed | COST-MINIMIZATION OF VILANTEROL / UMECLIDINIUM VERSUS OLODATEROL / TIOTROPIUM IN THE BASIC THERAPY OF SEVERE AND VERY SEVERE COPD |
| title_short | COST-MINIMIZATION OF VILANTEROL / UMECLIDINIUM VERSUS OLODATEROL / TIOTROPIUM IN THE BASIC THERAPY OF SEVERE AND VERY SEVERE COPD |
| title_sort | cost minimization of vilanterol umeclidinium versus olodaterol tiotropium in the basic therapy of severe and very severe copd |
| topic | chronic obstructive pulmonary disease copd long-acting beta-agonists laba long-acting anticholinergics laac vilantererol umeclidinum bromide olodaterol tiotropium bromide fixed combination cost minimization analysis cost-effectiveness analysis budget impact analysis |
| url | https://www.pharmacoeconomics.ru/jour/article/view/196 |
| work_keys_str_mv | AT egkosolapov costminimizationofvilanterolumeclidiniumversusolodateroltiotropiuminthebasictherapyofsevereandveryseverecopd AT fskochenkov costminimizationofvilanterolumeclidiniumversusolodateroltiotropiuminthebasictherapyofsevereandveryseverecopd AT nlpogudina costminimizationofvilanterolumeclidiniumversusolodateroltiotropiuminthebasictherapyofsevereandveryseverecopd AT dvblinov costminimizationofvilanterolumeclidiniumversusolodateroltiotropiuminthebasictherapyofsevereandveryseverecopd AT nlbondarenko costminimizationofvilanterolumeclidiniumversusolodateroltiotropiuminthebasictherapyofsevereandveryseverecopd AT avkaraulov costminimizationofvilanterolumeclidiniumversusolodateroltiotropiuminthebasictherapyofsevereandveryseverecopd |